Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9132027rdf:typepubmed:Citationlld:pubmed
pubmed-article:9132027lifeskim:mentionsumls-concept:C0085080lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C0376448lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C1171362lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C1145667lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C0439799lld:lifeskim
pubmed-article:9132027lifeskim:mentionsumls-concept:C0174725lld:lifeskim
pubmed-article:9132027pubmed:issue12lld:pubmed
pubmed-article:9132027pubmed:dateCreated1997-4-29lld:pubmed
pubmed-article:9132027pubmed:abstractTextVoltage-gated potassium (K(V)) channels play key roles in setting the resting potential and in the activation cascade of human peripheral T lymphocytes. Margatoxin (MgTX), a 39-amino acid peptide from Centruroides margaritatus, is a potent inhibitor of lymphocyte K(V) channels. The binding of monoiodotyrosinyl margatoxin ([125I]MgTX) to plasma membranes prepared from either Jurkat cells, a human leukemic T cell line, or CHO cells stably transfected with the Shaker-type voltage-gated K+ channel, K(V)1.3, has been used to investigate the properties of lymphocyte K(V) channels. These data were compared with [125I]MgTX binding to heterotetrameric K(V) channels in rat brain synaptic plasma membranes [Knaus, H. G., et al. (1995) Biochemistry 34, 13627-13634]. The affinity for [125I]MgTX is 100-200 fM in either Jurkat or CHO/K(V)1.3 membranes, and the receptor density is 20-120 fmol/mg in Jurkat membranes or 1000 fmol/mg in CHO/K(V)1.3 membranes. In contrast to rat brain, [125I]MgTX binding to Jurkat and CHO/K(V)1.3 membranes exhibits an absolute requirement for K+, with no potentiation of binding by Na+. K(V)1.3 was the only K(V)1 series channel present in either CHO/K(V)1.3 or Jurkat plasma membranes as determined by immunoprecipitation of [125I]MgTX binding or by Western blot analyses using sequence-specific antibodies prepared against members of the K(V)1 family. The relative potencies of a series of peptidyl K(V) channel inhibitors was essentially the same for inhibition of [125I]MgTX binding to Jurkat, CHO, or rat brain membranes and for blocking 86Rb+ efflux from the CHO/K(V)1.3 cells, except that alpha-dendrotoxin was more potent at blocking binding to rat brain membranes than in the other assays. The characteristics of [125I]MgTX binding, the antibody profiles, and the effects of the peptidyl K(V) inhibitors all indicate that the [125I]MgTX receptor in Jurkat lymphocytes is comprised of a homomultimer of K(V)1.3, unlike the heteromultimeric arrangement of the receptor in rat brain.lld:pubmed
pubmed-article:9132027pubmed:languageenglld:pubmed
pubmed-article:9132027pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:citationSubsetIMlld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9132027pubmed:statusMEDLINElld:pubmed
pubmed-article:9132027pubmed:monthMarlld:pubmed
pubmed-article:9132027pubmed:issn0006-2960lld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:KochRRlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:KaczorowskiG...lld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:StevensSSlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:GarciaM LMLlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:LeonardR JRJlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:SlaughterR...lld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:KnausH GHGlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:FelixJ PJPlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:HelmsL MLMlld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:BugianesiR...lld:pubmed
pubmed-article:9132027pubmed:authorpubmed-author:WannerS GSGlld:pubmed
pubmed-article:9132027pubmed:issnTypePrintlld:pubmed
pubmed-article:9132027pubmed:day25lld:pubmed
pubmed-article:9132027pubmed:volume36lld:pubmed
pubmed-article:9132027pubmed:ownerNLMlld:pubmed
pubmed-article:9132027pubmed:authorsCompleteYlld:pubmed
pubmed-article:9132027pubmed:pagination3737-44lld:pubmed
pubmed-article:9132027pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:meshHeadingpubmed-meshheading:9132027-...lld:pubmed
pubmed-article:9132027pubmed:year1997lld:pubmed
pubmed-article:9132027pubmed:articleTitleMargatoxin binds to a homomultimer of K(V)1.3 channels in Jurkat cells. Comparison with K(V)1.3 expressed in CHO cells.lld:pubmed
pubmed-article:9132027pubmed:affiliationDepartment of Membrane Biochemistry and Biophysics, Merck Research Laboratories, Rahway, New Jersey 07065, USA.lld:pubmed
pubmed-article:9132027pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9132027pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9132027pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9132027lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9132027lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9132027lld:pubmed